Jean Siebenaler | Medical Director
OptumInsight Life Sciences

Jean Siebenaler, Medical Director, OptumInsight Life Sciences

Share this

Appearances at this years' conference:

Day One Wednesday 21 March 2012


@ 16.40
Pragmatic Clinical Trials (PCTs) - Considerations in Late Phase Research

Learning Objectives:

1. Will be able to summarize the key reasons for designing a pragmatic trial versus an explanatory randomized trial or observational study design
2. Will be able to identify the key pragmatic clinical trial design and reporting elements

This brief presentation on pragmatic clinical trials (PCT) will highlight the role and the value of these increasingly popular study designs in Late Phase and Outcomes research. Differences between PCTs, explanatory RCTs and observational designs will be reviewed, and the important key design and reporting elements of PCTs will be discussed in detail.
 

  • › Jean Siebenaler, Medical Director, OptumInsight Life Sciences
Sponsors
Session Facilitators
PRA International at Late Phase Drug Development World Americas 2012
Session presentation sponsor
Medidata Solutions Inc at Late Phase Drug Development World Americas 2012
Session presentation sponsor
OptumInsight at Late Phase Drug Development World Americas 2012
Session presentation sponsor
Oracle Corporation UK Limited at Late Phase Drug Development World Americas 2012
Session presentation sponsor
CRF Health at Late Phase Drug Development World Americas 2012
Session presentation sponsor
PharmaNet/i3 at Late Phase Drug Development World Americas 2012
Session presentation sponsor
United BioSource Corporation at Late Phase Drug Development World Americas 2012